Log In
Print
BCIQ
Print
Print this Print this
 

Banzel, Inovelon, rufinamide (Banzel oral suspension) (E2080)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionTriazole derivative
Molecular Target Sodium channel
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationLennox-Gastaut syndrome
Indication DetailsAdjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ages 4 and up
Regulatory Designation

Switzerland - Orphan Drug (Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ages 4 and up)

Partner

Eisai Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today